399 related articles for article (PubMed ID: 24300416)
1. Adult asthma biomarkers.
Kim MA; Shin YS; Pham le D; Park HS
Curr Opin Allergy Clin Immunol; 2014 Feb; 14(1):49-54. PubMed ID: 24300416
[TBL] [Abstract][Full Text] [Related]
2. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients.
Jia G; Erickson RW; Choy DF; Mosesova S; Wu LC; Solberg OD; Shikotra A; Carter R; Audusseau S; Hamid Q; Bradding P; Fahy JV; Woodruff PG; Harris JM; Arron JR;
J Allergy Clin Immunol; 2012 Sep; 130(3):647-654.e10. PubMed ID: 22857879
[TBL] [Abstract][Full Text] [Related]
3. Serum periostin levels serve as a biomarker for both eosinophilic airway inflammation and fixed airflow limitation in well-controlled asthmatics.
Takahashi K; Meguro K; Kawashima H; Kashiwakuma D; Kagami SI; Ohta S; Ono J; Izuhara K; Iwamoto I
J Asthma; 2019 Mar; 56(3):236-243. PubMed ID: 29648484
[TBL] [Abstract][Full Text] [Related]
4. Utility of serum periostin in combination with exhaled nitric oxide in the management of asthma.
Nagasaki T; Matsumoto H; Izuhara K;
Allergol Int; 2017 Jul; 66(3):404-410. PubMed ID: 28256388
[TBL] [Abstract][Full Text] [Related]
5. The chitinase-like protein YKL-40: a possible biomarker of inflammation and airway remodeling in severe pediatric asthma.
Konradsen JR; James A; Nordlund B; Reinius LE; Söderhäll C; Melén E; Wheelock AM; Lödrup Carlsen KC; Lidegran M; Verhoek M; Boot RG; Dahlén B; Dahlén SE; Hedlin G
J Allergy Clin Immunol; 2013 Aug; 132(2):328-35.e5. PubMed ID: 23628340
[TBL] [Abstract][Full Text] [Related]
6. External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma.
Wagener AH; de Nijs SB; Lutter R; Sousa AR; Weersink EJ; Bel EH; Sterk PJ
Thorax; 2015 Feb; 70(2):115-20. PubMed ID: 25422384
[TBL] [Abstract][Full Text] [Related]
7. Type 2 innate lymphoid cells: A novel biomarker of eosinophilic airway inflammation in patients with mild to moderate asthma.
Liu T; Wu J; Zhao J; Wang J; Zhang Y; Liu L; Cao L; Liu Y; Dong L
Respir Med; 2015 Nov; 109(11):1391-6. PubMed ID: 26459159
[TBL] [Abstract][Full Text] [Related]
8. Serum periostin: a novel biomarker for asthma management.
Matsumoto H
Allergol Int; 2014 Jun; 63(2):153-60. PubMed ID: 24759559
[TBL] [Abstract][Full Text] [Related]
9. Periostin levels and eosinophilic inflammation in poorly-controlled asthma.
Simpson JL; Yang IA; Upham JW; Reynolds PN; Hodge S; James AL; Jenkins C; Peters MJ; Jia G; Holweg CT; Gibson PG
BMC Pulm Med; 2016 Apr; 16(1):67. PubMed ID: 27130294
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in asthma biomarker research.
Leung TF; Ko FW; Wong GW
Ther Adv Respir Dis; 2013 Oct; 7(5):297-308. PubMed ID: 23907809
[TBL] [Abstract][Full Text] [Related]
11. The chitinase-like protein YKL-40 is not a useful biomarker for severe persistent asthma in children.
Santos CB; Davidson J; Covar RA; Spahn JD
Ann Allergy Asthma Immunol; 2014 Sep; 113(3):263-6. PubMed ID: 24954373
[TBL] [Abstract][Full Text] [Related]
12. Combined Assessment of Serum Periostin and YKL-40 May Identify Asthma-COPD Overlap.
Shirai T; Hirai K; Gon Y; Maruoka S; Mizumura K; Hikichi M; Holweg C; Itoh K; Inoue H; Hashimoto S
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):134-145.e1. PubMed ID: 29981861
[TBL] [Abstract][Full Text] [Related]
13. Predicting asthma morbidity in children using proposed markers of Th2-type inflammation.
Konradsen JR; Skantz E; Nordlund B; Lidegran M; James A; Ono J; Ohta S; Izuhara K; Dahlén SE; Alving K; Hedlin G
Pediatr Allergy Immunol; 2015 Dec; 26(8):772-9. PubMed ID: 26266838
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers for severe allergic asthma in children: could they be useful to guide disease control and use of omalizumab?
Amat F; Labbé A
Expert Rev Respir Med; 2018 Jun; 12(6):475-482. PubMed ID: 29741411
[TBL] [Abstract][Full Text] [Related]
15. Periostin, a novel biomarker of TH2-driven asthma.
Parulekar AD; Atik MA; Hanania NA
Curr Opin Pulm Med; 2014 Jan; 20(1):60-5. PubMed ID: 24247042
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers for differentiation of patients with asthma and chronic obstructive pulmonary disease.
Katoh S; Ikeda M; Shirai R; Abe M; Ohue Y; Kobashi Y; Oka M
J Asthma; 2018 Oct; 55(10):1052-1058. PubMed ID: 29035604
[TBL] [Abstract][Full Text] [Related]
17. A pathophysiological approach for FeNO: A biomarker for asthma.
Ricciardolo FL; Sorbello V; Ciprandi G
Allergol Immunopathol (Madr); 2015; 43(6):609-16. PubMed ID: 25796309
[TBL] [Abstract][Full Text] [Related]
18. Sputum periostin in patients with different severe asthma phenotypes.
Bobolea I; Barranco P; Del Pozo V; Romero D; Sanz V; López-Carrasco V; Canabal J; Villasante C; Quirce S
Allergy; 2015 May; 70(5):540-6. PubMed ID: 25631525
[TBL] [Abstract][Full Text] [Related]
19. Improving the diagnosis of eosinophilic asthma.
Coumou H; Bel EH
Expert Rev Respir Med; 2016 Oct; 10(10):1093-103. PubMed ID: 27624868
[TBL] [Abstract][Full Text] [Related]
20. Cutoff point for exhaled nitric oxide corresponding to 3% sputum eosinophils.
Alvarez-Puebla MJ; Olaguibel Rivera JM; Almudevar E; Echegoyen AA; de Esteban Chocarro B; Cambra K
J Investig Allergol Clin Immunol; 2015; 25(2):107-11. PubMed ID: 25997303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
